Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma

Leukemia & Lymphoma
Hirokazu NagaiMorio Sawamura

Abstract

Rituximab has markedly improved the outcomes of B cell lymphoma, and its maintenance has been shown to be beneficial in low grade B cell lymphoma (LGBCL). We conducted a multicenter, phase II trial of intensive rituximab induction and maintenance therapy for LGBCL to optimize the rituximab monotherapy. Patients with newly diagnosed or rituximab naïve relapsed LGBCL received 8 weekly rituximab as induction, then continued maintenance therapy with rituximab for 4 weeks at 6-month intervals. The primary endpoint was the overall response rate (ORR). Forty-five patients were enrolled from 2005 to 2009 and 36 were eligible. The ORR was 83.3% (30/36) with a complete response rate of 72.2% (26/36). The 3-year progression-free survival (PFS) was 76.7% with a median follow-up of 43.0 months. Five grade three toxicities were observed (no grade 4). Our findings suggest that this regimen demonstrates high activity with durable PFS and minimal toxicity in LGBCL patients.

References

Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L D PiroV Jain
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T IgarashiUNKNOWN IDEC-C2B8 Study Group in Japan
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Jul 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert MarcusGeorge Stein
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni MartinelliMichele Ghielmini
Sep 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takashi WatanabeTomomitsu Hotta
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Peter McLaughlin
Mar 1, 2014·Leukemia·W Hiddemann, B D Cheson
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brad S KahlSandra J Horning

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.